Donohue JF, et al. - In COPD patients treated with arformoterol, health-related quality of life (HRQoL) was assessed using St George’s Respiratory Questionnaire (SGRQ) and symptom response profiles were analyzed via post hoc growth mixture model (GMM) analysis. It was found that arformoterol not only significantly improved HRQoL but also could be particularly effective in improving lung function and attenuating hospitalizations among patients who were unable to quit smoking or presented with more severe symptoms.